<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01510704</url>
  </required_header>
  <id_info>
    <org_study_id>DP10006</org_study_id>
    <nct_id>NCT01510704</nct_id>
  </id_info>
  <brief_title>Phase II Dose-ranging Study of APD421 in PONV</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, Dose-ranging Phase II Study of APD421 for the Prevention of Post-operative Nausea and Vomiting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acacia Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acacia Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of different doses of APD421 in the prevention of
      post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV.
      Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any
      surgical technique), cholecystectomy (any surgical technique) or &quot;other&quot; elective surgery
      scheduled to last at least one hour from induction of anaesthesia), requiring at least one
      overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past
      history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use
      for post-operative analgesia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Nausea or Vomiting</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose APD421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose APD421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose APD421</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg dose level</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD421</intervention_name>
    <description>IV</description>
    <arm_group_label>Low dose APD421</arm_group_label>
    <arm_group_label>Mid Dose APD421</arm_group_label>
    <arm_group_label>High Dose APD421</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Male or female patients ≥ 18 years of age

          2. Ability and willingness to give written informed consent

          3. Patients undergoing elective surgery under general anaesthesia requiring at least one
             overnight stay in hospital for either:

               1. Hysterectomy (any surgical technique)

               2. Cholecystectomy (any surgical technique)

               3. Other elective surgery requiring overnight admission to hospital and scheduled to
                  last at least 1 hour from induction of anaesthesia

          4. Patients with at least 2 of the following risk factors for PONV:

               1. Past history of PONV and/or motion sickness

               2. Habitual non-smoking status

               3. Female sex

               4. Expected to receive opioid analgesia post-operatively

          5. American Society of Anesthesiologists (ASA) risk score I-III

          6. Adequate cardiac, hepatic and renal function

               -  QTc interval &lt; 500 ms

               -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &lt; 5 x
                  upper limit normal (ULN)

               -  Bilirubin &lt; 3 x ULN

               -  Creatinine &lt; 2 x ULN

          7. Adequate haematological function

               -  Haemoglobin ≥ 9 g/dL

               -  White blood count ≥ 3.0 x 109/L

               -  Platelet count ≥ 100 x 109/L

          8. For females of child-bearing potential: ability and willingness to use a highly
             effective form of contraception (e.g., abstinence from sexual intercourse, surgical
             sterilisation (of subject or partner) or a double-barrier method of contraception such
             as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in
             conjunction with partner's use of a condom) between the date of screening and at least
             48 hours after administration of study drug.

        Exclusion Criteria

          1. Patients undergoing outpatient/day case surgery

          2. Patients undergoing surgery where the patient is expected to remain ventilated for a
             period after surgery

          3. Patients undergoing intra-thoracic, transplant or central nervous system surgery

          4. Patients receiving a local anaesthetic/regional neuraxial (intrathecal or epidural)
             block

          5. Patients who are expected to need a naso- or oral-gastric tube in situ after surgery
             is completed

          6. Patients receiving the active ingredient of APD421 for any indication within the last
             2 weeks

          7. Patients who are allergic to the active ingredient or any of the excipients of APD421

          8. Patients with a pre-existing vestibular disorder or history of dizziness

          9. Patients with pre-existing nausea or vomiting in the 24 hours before surgery

         10. Patients treated with regular anti-emetic therapy including corticosteroids

         11. Patients being treated with medications which could induce torsades de pointes,
             including Class Ia antiarrhythmic agents such as quinidine, disopyramide,
             procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and
             other medications such as bepridil, cisapride, thioridazine, methadone, IV
             erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin

         12. Patients being treated with levodopa

         13. Patients who are pregnant or breast feeding

         14. Patients with a history of alcohol abuse

         15. Patients with pre-existing, clinically significant cardiac arrhythmia

         16. Patients diagnosed with Parkinson's disease

         17. Patients who have received anti-cancer chemotherapy in the previous 4 weeks

         18. Patients with a history of epilepsy

         19. Any other concurrent disease or illness that, in the opinion of the investigator makes
             the patient unsuitable for the study

         20. Patients who have participated in a previous study within the last 28 days (French
             sites only: Patients who have participated in a previous study within the last 6
             months, if required by national or local regulations)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Kranke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Würzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital mère enfant</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital FOCH</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautepierre Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Aue</name>
      <address>
        <city>Aue</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps University</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2012</study_first_posted>
  <results_first_submitted>May 15, 2013</results_first_submitted>
  <results_first_submitted_qc>May 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2013</results_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
        </group>
        <group group_id="P2">
          <title>Low Dose APD421</title>
          <description>1mg dose level</description>
        </group>
        <group group_id="P3">
          <title>Mid Dose APD421</title>
          <description>5mg dose level</description>
        </group>
        <group group_id="P4">
          <title>High Dose APD421</title>
          <description>20mg dose level</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Low Dose APD421</title>
          <description>1mg dose level</description>
        </group>
        <group group_id="B3">
          <title>Mid Dose APD421</title>
          <description>5mg dose level</description>
        </group>
        <group group_id="B4">
          <title>High Dose APD421</title>
          <description>20mg dose level</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="53"/>
            <count group_id="B5" value="215"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.1" spread="13.6"/>
                    <measurement group_id="B2" value="50" spread="14.5"/>
                    <measurement group_id="B3" value="50" spread="16.2"/>
                    <measurement group_id="B4" value="50.7" spread="15.7"/>
                    <measurement group_id="B5" value="49.9" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Nausea or Vomiting</title>
        <time_frame>24 hours</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Low Dose APD421</title>
            <description>1mg dose level</description>
          </group>
          <group group_id="O3">
            <title>Mid Dose APD421</title>
            <description>5mg dose level</description>
          </group>
          <group group_id="O4">
            <title>High Dose APD421</title>
            <description>20mg dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Nausea or Vomiting</title>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Low Dose APD421</title>
          <description>1mg dose level</description>
        </group>
        <group group_id="E3">
          <title>Mid Dose APD421</title>
          <description>5mg dose level</description>
        </group>
        <group group_id="E4">
          <title>High Dose APD421</title>
          <description>20mg dose level</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>WOUND HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="54"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="58"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="54"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="54"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="58"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="50"/>
                <counts group_id="E4" events="27" subjects_affected="27" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Gabriel Fox</name_or_title>
      <organization>Acacia Pharma Ltd</organization>
      <email>gabrielfox@acaciapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

